Pulmonx (NASDAQ:LUNG) Announces Quarterly Earnings Results

Pulmonx (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07, Zacks reports. The firm had revenue of $18.85 million for the quarter, compared to analysts’ expectations of $17.54 million. Pulmonx had a negative return on equity of 46.63% and a negative net margin of 88.60%. During the same quarter last year, the business posted ($0.42) EPS. Pulmonx updated its FY 2024 guidance to EPS.

Pulmonx Stock Up 21.6 %

LUNG traded up $1.67 during midday trading on Thursday, hitting $9.39. The company had a trading volume of 907,636 shares, compared to its average volume of 510,685. Pulmonx has a 52 week low of $7.11 and a 52 week high of $14.84. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $361.89 million, a price-to-earnings ratio of -6.07 and a beta of 0.66. The stock’s 50 day moving average price is $8.65 and its 200 day moving average price is $10.69.

Insider Transactions at Pulmonx

In other news, CEO Glendon E. French III sold 6,954 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $9.06, for a total transaction of $63,003.24. Following the completion of the sale, the chief executive officer now directly owns 1,116,758 shares of the company’s stock, valued at $10,117,827.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Glendon E. French III sold 6,954 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $9.06, for a total transaction of $63,003.24. Following the sale, the chief executive officer now directly owns 1,116,758 shares in the company, valued at approximately $10,117,827.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Glendon E. French III sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.60, for a total transaction of $292,000.00. Following the sale, the chief executive officer now owns 1,121,344 shares in the company, valued at $16,371,622.40. The disclosure for this sale can be found here. Insiders sold a total of 39,032 shares of company stock valued at $469,012 over the last three months. Corporate insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $17.00 price objective on shares of Pulmonx in a research report on Wednesday, April 3rd. Stifel Nicolaus raised their price target on Pulmonx from $15.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Wells Fargo & Company restated an “equal weight” rating and set a $14.00 target price (down previously from $16.00) on shares of Pulmonx in a report on Friday, February 23rd. Finally, Citigroup lifted their price objective on Pulmonx from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.83.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.